Home › Trials › NCT07339423

AMAZE 1: NNC0487-0111 for adults with excess body weight

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)

Phase 3 Interventional Novo Nordisk A/S · NCT07339423

This trial tests whether weekly injections of NNC0487-0111 help adults with excess body weight lose weight compared with a placebo.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment1150 (estimated)
Ages18 Years and up
SexAll
SponsorNovo Nordisk A/S Industry-sponsored
Locations72 sites (Miramar, Florida and 71 other locations)
Trial IDNCT07339423 on ClinicalTrials.gov

What this trial studies

AMAZE 1 is a phase 3, randomized, placebo-controlled trial in which participants receive once-weekly subcutaneous injections of either NNC0487-0111 or a matched placebo. Treatment assignment is by chance and the placebo is matched to the active injection. Key eligibility excludes people with diagnosed diabetes or an HbA1c of 6.5% or higher and those with prior treatment with GLP‑1–based or amylin drugs. The study is sponsored by Novo Nordisk and is being conducted at several clinic sites in Florida and Georgia.

Who should consider this trial

Good fit: Adults with excess body weight who have a history of at least one unsuccessful diet-based weight-loss attempt, have HbA1c below 6.5%, do not have diabetes, and have not been treated with GLP‑1–based or amylin therapies are the intended participants.

Not a fit: People with diagnosed type 1 or type 2 diabetes, an HbA1c of 6.5% or higher, or recent use of GLP‑1/gastric inhibitory peptide receptor agonists or amylin analogues are excluded and unlikely to benefit from joining this trial.

Why it matters

Potential benefit: If successful, NNC0487-0111 could help people with excess body weight lose clinically meaningful weight and reduce obesity-related health risks.

How similar studies have performed: Other injectable GLP‑1–based and dual incretin therapies have shown substantial weight loss in late‑phase trials, though NNC0487-0111 itself is a distinct investigational agent.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

* Male or female (sex at birth).
* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
* History of at least one self-reported unsuccessful dietary effort to lose body weight.

Key Exclusion Criteria:

* HbA1c ≥ 6.5% (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening.
* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

Where this trial is running

Miramar, Florida and 71 other locations

+22 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Obesity
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.